Marginal Zone Lymphoma

Marginal zone lymphoma can sound like something involving maps, property lines, or an argument over where to place the backyard fence. In reality, it is a group of uncommon blood cancers that develop from B lymphocytes, the immune cells responsible for making antibodies.

Most marginal zone lymphomas grow slowly. Some people need treatment soon after diagnosis, while others can safely remain under active monitoring for months or years. The right approach depends on the lymphoma subtype, its location, symptoms, laboratory findings, overall health, and whether an infection or autoimmune condition is helping drive the disease.

This guide explains the three main types of marginal zone lymphoma, common symptoms, diagnostic tests, treatment options, prognosis, and what living with this condition may feel like in everyday life.

Research basis:

What Is Marginal Zone Lymphoma?

Marginal zone lymphoma, commonly abbreviated as MZL, is a type of B-cell non-Hodgkin lymphoma. It begins when certain B lymphocytes acquire abnormal changes that allow them to survive and multiply when they ordinarily would not.

The name comes from the “marginal zone,” an area near the outer edge of lymphoid tissue where specialized B cells normally respond to infections. When these cells become malignant, they may accumulate in lymph nodes, the spleen, bone marrow, blood, or organs outside the traditional lymphatic system.

MZL is usually classified as an indolent lymphoma, meaning it often progresses slowly. “Indolent” does not mean imaginary, harmless, or deserving of less attention. It means doctors frequently have time to evaluate the disease carefully and choose treatment according to its behavior rather than racing toward the most aggressive therapy available.

The Three Main Types of Marginal Zone Lymphoma

1. Extranodal Marginal Zone Lymphoma of MALT

Extranodal marginal zone lymphoma develops outside the lymph nodes. It is also called mucosa-associated lymphoid tissue lymphoma, or MALT lymphoma.

The stomach is the most familiar location, but MALT lymphoma can also appear in the salivary glands, thyroid, lungs, skin, intestines, breasts, or tissues around the eyes. Symptoms vary because a lymphoma in the stomach behaves differently from one near the eye or in the lung.

Gastric MALT lymphoma is strongly associated with chronic infection by Helicobacter pylori, better known as H. pylori. In many early-stage cases, eliminating the infection with antibiotics and acid-suppressing medication can cause the lymphoma to regress. That is a rather unusual cancer treatment plan: attack the bacteria, and the tumor may lose the inflammatory environment that was helping it survive.

2. Splenic Marginal Zone Lymphoma

Splenic marginal zone lymphoma mainly affects the spleen, bone marrow, and blood. It may cause the spleen to become enlarged, producing pressure, discomfort, or a feeling of fullness beneath the left ribs. Some people feel full after eating only a small amount because the enlarged spleen presses against the stomach.

Bone marrow involvement may contribute to low red blood cell, white blood cell, or platelet counts. This can lead to fatigue, frequent infections, easy bruising, or bleeding. Splenic MZL has also been linked to chronic hepatitis C infection in some patients.

3. Nodal Marginal Zone Lymphoma

Nodal marginal zone lymphoma begins primarily in the lymph nodes. It is the least common of the three major subtypes and is diagnosed only after doctors exclude extranodal and splenic disease.

People may notice painless swelling in the neck, armpit, or groin. Because several lymphomas can look similar under the microscope, an expert hematopathology review is often particularly helpful.

Research basis:

What Causes Marginal Zone Lymphoma?

Doctors usually cannot identify one single cause. MZL develops through acquired changes in B-cell DNA, often in an environment of prolonged immune stimulation. The changes are generally acquired during life rather than directly inherited from a parent.

Known associations include:

• H. pylori infection: Closely associated with many gastric MALT lymphomas.
• Hepatitis C: Associated with some cases of splenic marginal zone lymphoma.
• Autoimmune disease: Sjögren syndrome is linked to salivary-gland MALT lymphoma, while Hashimoto thyroiditis is associated with thyroid lymphoma.
• Chronic inflammation: Long-term immune activation may encourage abnormal B-cell growth.
• Increasing age: MZL is diagnosed more often in older adults, although younger adults can develop it.

Having one of these risk factors does not mean a person will develop lymphoma. Most people with H. pylori, hepatitis C, or an autoimmune disorder never develop MZL. The condition is also not contagious. You cannot catch lymphoma from another person, even when an infection contributed to that person’s disease.

Research basis:

Marginal Zone Lymphoma Symptoms

Some people have no noticeable symptoms. Their lymphoma may be discovered during an examination, imaging study, endoscopy, or blood test performed for an unrelated reason.

Possible general symptoms include:

• Painless swollen lymph nodes
• Persistent fatigue
• Unexplained fever
• Drenching night sweats
• Unintentional weight loss
• Frequent infections
• Easy bruising or bleeding
• Abdominal pressure, pain, or swelling

Doctors sometimes call fever, drenching night sweats, and significant unexplained weight loss “B symptoms.” They are less common in indolent MZL than in aggressive lymphomas, but they deserve prompt medical attention.

Symptoms by Disease Location

Gastric MALT lymphoma may cause indigestion, nausea, upper abdominal discomfort, reduced appetite, anemia, or gastrointestinal bleeding. Lymphoma around the eye may produce swelling, redness, double vision, or a visible mass. Lung involvement may cause coughing or shortness of breath, while salivary-gland disease may appear as persistent swelling near the jaw.

These symptoms have many noncancerous explanations. A swollen lymph node after a respiratory infection is far more likely to be reacting to germs than secretly rehearsing for a lymphoma documentary. However, unexplained symptoms that persist, worsen, or appear together should be evaluated.

Research basis:

How Marginal Zone Lymphoma Is Diagnosed

Diagnosis generally begins with a medical history and physical examination. The doctor may check lymph nodes and look for enlargement of the spleen or liver.

Biopsy

A biopsy is usually required to confirm lymphoma. Depending on the location, a doctor may remove a lymph node, collect a core of tissue, take a skin sample, or obtain stomach tissue during an upper endoscopy.

A pathologist examines the sample and may perform immunohistochemistry, flow cytometry, chromosome analysis, or molecular testing. These studies help establish that the abnormal cells are B lymphocytes and distinguish MZL from other small B-cell lymphomas.

Blood Tests

A complete blood count measures red cells, white cells, and platelets. Additional tests may assess liver and kidney function, lactate dehydrogenase levels, antibody proteins, and evidence of infection.

Testing for hepatitis B is important before anti-CD20 therapy because treatment can reactivate a past infection. Depending on the subtype, doctors may also test for H. pylori, hepatitis C, or other organisms.

Imaging and Additional Procedures

CT scans are commonly used to evaluate lymph nodes and internal organs. PET scans may be helpful in selected cases, although MZL does not always absorb the radioactive tracer as intensely as more aggressive lymphomas.

A bone marrow biopsy may be recommended when the results could affect staging or treatment. Gastric MALT lymphoma often requires endoscopy with multiple biopsies because the disease can be patchy and may not announce itself with a convenient flashing sign.

Research basis:

Understanding MZL Stages

Marginal zone lymphoma is generally assigned a stage from I through IV. Stage I is limited to one lymphatic area or one extranodal site. Stage II involves multiple areas on the same side of the diaphragm. Stage III appears on both sides of the diaphragm, and stage IV may involve bone marrow or other distant organs.

Stage IV sounds alarming, but lymphoma staging differs from staging for many solid tumors. Because indolent lymphoma cells naturally travel through the lymphatic system and blood, advanced-stage MZL can still be highly manageable. Treatment decisions depend on symptoms, tumor burden, organ function, growth rate, and overall healthnot on the Roman numeral alone.

Marginal Zone Lymphoma Treatment

There is no single treatment plan for everyone. A person with localized gastric MALT lymphoma may begin with antibiotics, while someone with symptomatic splenic disease may receive an anti-CD20 antibody. Another patient may need no immediate treatment at all.

Active Monitoring

People with slow-growing, low-volume MZL and no troublesome symptoms may be offered active monitoring, also called watchful waiting. This means scheduled appointments, examinations, and laboratory tests without immediate anticancer treatment.

Active monitoring is not neglect. It avoids treatment side effects until therapy is likely to provide a clear benefit. Treatment can begin if symptoms develop, blood counts decline, organs are threatened, or the lymphoma shows meaningful progression.

Treating an Associated Infection

Early gastric MALT lymphoma associated with H. pylori is commonly treated with a combination of antibiotics and a proton pump inhibitor. Regression is not instant and may take several months, so follow-up endoscopies and biopsies are essential.

For selected patients with hepatitis C-associated splenic MZL, direct-acting antiviral therapy may improve both the infection and the lymphoma. Decisions should involve specialists familiar with liver disease and lymphoma.

Radiation Therapy

Localized extranodal or nodal MZL can be highly sensitive to radiation. Modern involved-site radiation focuses treatment on the affected area while limiting exposure to surrounding tissue.

Potential side effects depend on the location. Treatment near the stomach may cause nausea, while radiation near the eye can cause dryness or irritation. The radiation team designs the smallest reasonable field, because healthy organs are terrible volunteers for unnecessary treatment.

Immunotherapy

Rituximab is a monoclonal antibody that targets CD20, a protein found on many B cells. It may be used alone or combined with chemotherapy. Infusion reactions can occur, especially during the first dose, but nurses monitor closely and can slow or pause the infusion when needed.

Chemoimmunotherapy

When systemic treatment is required, commonly considered combinations may include bendamustine plus rituximab or other rituximab-based regimens. The choice depends on age, health, disease behavior, previous treatment, and the need for a rapid response.

Possible side effects include fatigue, nausea, low blood counts, infection risk, rash, and temporary changes in appetite. Supportive medicines and dose adjustments can make treatment more manageable.

Surgery

Surgery is not the main treatment for most lymphomas. However, removal of the spleen may still be considered for selected people with splenic MZL, particularly when severe enlargement or low blood counts are causing problems. Rituximab-based treatment has reduced the need for splenectomy in many cases.

Targeted Therapy for Relapsed MZL

Zanubrutinib is a Bruton tyrosine kinase inhibitor approved in the United States for adults with relapsed or refractory MZL after at least one anti-CD20-based regimen. Lenalidomide combined with rituximab is another option for some previously treated patients.

Targeted medicines are not side-effect-free. Depending on the drug, risks may include bleeding, infection, low blood counts, heart rhythm problems, diarrhea, rash, or interactions with other medications. Patients should provide their oncology team with a complete list of prescriptions, over-the-counter drugs, and supplements.

Stem cell transplantation, cellular therapy, and intensive chemotherapy are generally reserved for highly selected situations, such as multiply relapsed disease or transformation into an aggressive lymphoma. Clinical trials may provide access to bispecific antibodies and other emerging treatments.

Research basis:

Prognosis and the Possibility of Recurrence

Most marginal zone lymphomas have a favorable overall outlook compared with aggressive non-Hodgkin lymphomas. Localized disease may remain in remission for many years, and infection-associated gastric MALT lymphoma may resolve after successful eradication therapy.

Advanced MZL is often treated as a long-term condition. It may respond well, return later, and respond again to another treatment. Doctors therefore try to balance disease control with quality of life and long-term treatment effects.

A small proportion of cases transform into a faster-growing lymphoma, most often diffuse large B-cell lymphoma. Warning signs may include rapidly enlarging lymph nodes, worsening B symptoms, rising lactate dehydrogenase, or sudden progression after a previously quiet course. A new biopsy is often needed to confirm transformation.

Research basis:

Follow-Up Care and Healthy Daily Habits

Follow-up visits may include symptom reviews, physical examinations, and blood tests. Imaging is ordered when clinically useful rather than automatically at every visit for every patient.

There is no special diet proven to eliminate MZL. A balanced eating pattern can support energy, heart health, and recovery, but food should complement medical treatment rather than replace it. Patients should ask before taking herbal products because some supplements affect bleeding, liver enzymes, or drug metabolism.

Helpful daily priorities include staying physically active within personal limits, receiving recommended vaccines, protecting sleep, avoiding tobacco, limiting alcohol, and reporting infections early during immune-suppressing treatment.

Questions to Ask the Oncology Team

• Which type of marginal zone lymphoma do I have?
• Has my biopsy been reviewed by a lymphoma specialist?
• Is an infection or autoimmune condition associated with my disease?
• Do I need treatment now, or is active monitoring appropriate?
• What change would trigger treatment?
• What are the goals and likely side effects of the recommended therapy?
• Should I consider a clinical trial?
• Which symptoms should prompt an urgent call?

Experiences People Commonly Have With Marginal Zone Lymphoma

The following examples are composites based on patterns commonly discussed by patients and care teams. They are not individual medical histories and cannot predict another person’s experience.

The Diagnosis May Arrive by a Surprisingly Indirect Route

Many people do not begin their MZL story with a dramatic emergency. One common path starts with persistent indigestion, mild anemia, unusual swelling, or routine blood work that refuses to behave. A person may visit a primary care clinician, gastroenterologist, eye specialist, or ear, nose, and throat doctor before lymphoma enters the conversation.

This indirect route can create mixed emotions. There may be relief that the symptoms finally have a name, followed almost immediately by fear because that name contains the word “lymphoma.” Patients often describe the first oncology appointment as an information avalanche: subtype, stage, CD20, bone marrow, rituximab, monitoring. Bringing a trusted person and taking notes can make the avalanche feel more like manageable snowfall.

Watchful Waiting Can Feel Harder Than It Sounds

Some newly diagnosed patients expect cancer treatment to begin immediately. When the oncologist recommends active monitoring, they may wonder why everyone appears so calm while a cancer is technically still present.

Over time, many people learn that observation is an intentional strategy. They create routines around blood tests and appointments while continuing to work, travel, exercise, and care for family. Anxiety may increase before follow-up visits, a feeling sometimes called “scanxiety.” Planning enjoyable activities after appointments, using counseling services, and writing down symptoms instead of repeatedly searching online can help.

Infection-Directed Treatment Can Require Patience

A person with gastric MALT lymphoma related to H. pylori may initially be surprised to receive antibiotics rather than chemotherapy. Finishing several medications on schedule can be inconvenient, and the stomach may not immediately feel better.

The waiting period after treatment can also be frustrating. The bacteria may disappear before biopsy samples show complete lymphoma regression. Follow-up endoscopies are therefore important even when symptoms improve. For many patients, learning that slow biological change is expected makes the timeline easier to tolerate.

Rituximab Treatment Is Often More Routine Than Imagined

The first infusion is usually the longest because the clinical team administers the medicine cautiously and watches for reactions. Some patients experience chills, itching, flushing, fever, or throat irritation. When this happens, staff may pause the infusion, provide medication, and restart it more slowly.

Later treatments may feel more predictable. Patients often bring headphones, a blanket, snacks, and something to read, although naps sometimes defeat the reading plan. Fatigue can linger for a day or several days, so keeping the following schedule flexible is useful.

Symptoms and Energy Levels May Fluctuate

People living with MZL often report that fatigue is difficult to explain. It may not resemble ordinary sleepiness. A person can sleep well and still feel as though the battery icon never moved beyond 60 percent.

Fatigue can come from lymphoma, anemia, treatment, infection, stress, or poor sleep. Patients frequently benefit from tracking when it occurs and discussing changes with the care team rather than assuming it must simply be endured. Gentle walking, light resistance training, regular meals, and planned rest may help, but new or severe fatigue deserves medical evaluation.

Caregivers Have Their Own Adjustment Period

Family members may struggle with an illness that is serious but sometimes requires no immediate treatment. They may want to “do something” and become overprotective. Patients, meanwhile, may want ordinary conversation rather than becoming the full-time director of the household lymphoma department.

Clear communication helps. Practical assistancedriving to appointments, organizing medication lists, preparing meals, or handling insurance callsis often more useful than constant symptom checking. Both patients and caregivers may benefit from lymphoma support groups, oncology social workers, or mental health professionals.

Experience context:

Conclusion

Marginal zone lymphoma is a diverse group of usually slow-growing B-cell lymphomas. Its three main formsMALT, splenic, and nodal MZLcan look very different, so an accurate biopsy and subtype-specific evaluation are essential.

Treatment may range from active monitoring to antibiotics, antiviral therapy, radiation, rituximab, chemoimmunotherapy, targeted medicine, or participation in a clinical trial. Many people live well with MZL for years, although regular follow-up remains important because the disease can recur or, less commonly, transform into a more aggressive lymphoma.

The most useful plan is not necessarily the biggest treatment plan. It is the one matched to the individual disease, symptoms, health needs, and personal priorities.

Medical note: This article provides general education and is not a substitute for diagnosis or treatment from a hematologist-oncologist. Seek prompt medical care for rapidly enlarging lymph nodes, persistent fever, drenching night sweats, unexplained weight loss, severe abdominal pain, unusual bleeding, breathing difficulty, or signs of infection.